The Column Group (TCG) is a venture capital firm specializing in early-stage biotechnology companies, particularly those focused on drug discovery. TCG invests in companies based in the United States, making significant financial and operational commitments to develop unique scientific platforms capable of delivering breakthrough therapeutics. The firm typically participates in Series A through Series E funding rounds, reflecting its long-term approach to company building rather than a quick exit strategy.